Gates Package — page 243

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership ACTIV Executive Committee Francis Collins, M.D., Ph.D. (Co-Chair) Director NIH Paul Stoffels, M.D. (Co-Chair) Vice Chairman of the Executive Committee and Chief Scientific Officer Johnson & Johnson Gary Disbrow, Ph.D. Director Biomedical Advanced Research and Development Authority Mikael Dolsten, M.D., Ph.D. Chief Scientific Officer and President, Worldwide Research, Development and Medical Pfizer Anthony Fauci, M.D. Director, National Institute of Allergy and Infectious Diseases NIH Gary Gibbons, M.D. Director, National Heart, Lung, and Blood Institute NIH Peter Marks, M.D., Ph.D. Director, Center for Biologics Evaluation and Research U.S. Food and Drug Administration William Pao, M.D., Ph.D. Head of Pharma Research and Early Development (pRED) Roche Andrew Plump, M.D., Ph.D. President, Research & Development Takeda Pharmaceutical Co. Ltd. Janet Woodcock, M.D. Acting Commissioner U.S. Food and Drug Administration ACTIV Leadership Team James Anderson, M.D., Ph.D. Director, Division of Program Coordination, Planning, and Strategic Initiatives Office of the Director, NIH